HCL and Oracle partner on mhealth clinical trials
August 21, 2019
Indian technology company HCL Technologies is collaborating with Oracle Health Sciences to accelerate mhealth in clinical trials.
The collaboration aims to help life sciences companies execute and scale digital clinical trials to reduce the time and cost of drug development. The collaboration includes the availability of HCL’s Fit faster intelligent trials offering using California-based Oracle’s mhealth connector cloud service.
HCL’s Fit can be leveraged for a number of use cases, including improving patient engagement, collecting patient reported outcomes, monitoring patient safety, improving medication adherence or conducting e-visits during clinical trials to reduce patient and site burden. It can also be applied for drugs already launched commercially, such as for remote patient monitoring, gathering real world evidence or as an accompanying application for digital therapies.
“Although many of our customers have already established a strong case for leveraging mhealth technologies in clinical trials or digital therapies through proof of concept, we still see a chasm between the potential and actual adoption at scale,” said Shrikanth Shetty, executive vice president at HCL. “As a strategic partner to a large number of life sciences companies, HCL offers a comprehensive portfolio of services to navigate the journey from concept to adoption and continues to support them through the operational support services during or beyond clinical trials.”
The portfolio of mhealth services offered by the HCL and Oracle collaboration should help clients across different phases of their journey for adoption of mhealth technologies. Those looking to establish a business case or roadmap can engage HCL and Oracle for a six-to-eight-week proof-of-value package. Companies that have more advanced mhealth initiatives can leverage Fit using Oracle’s mhealth cloud as a service for a specific clinical trial.
HCL also provides implementation services for clients looking to adopt Oracle’s mhealth cloud as an enterprise platform across all mhealth initiatives. HCL further helps the clients scale the operations by providing managed services for supporting stakeholders engaged in the clinical trials, including patients and investigators across global trial locations.
“The life sciences industry has a great opportunity to radically change the way we understand and interact with patients during clinical trials,” said Jim Streeter, vice president for Oracle Health Sciences. “The collaboration between Oracle Health Sciences and HCL enables clinical teams to establish digitally enabled clinical trial processes and new digital trial methods such as remote patient monitoring. This is a very exciting time for the pharma industry as new technologies such as mhealth continue to accelerate clinical trials and speed time to market for patients who are waiting.”
HCL has a portfolio of services to support its clients throughout the clinical trial lifecycle, including business process redefinition, study setup, patient concierge, global device provisioning and kitting, multilingual support, customisation, or building trial specific applications.
HCL has the experience of supporting approximately 50,000 studies over 172,000 sites globally. On an annual basis, its support centres handle 400,000 requests from sites, investigators, nurses and subjects for clinical trials sponsored by large global pharmaceutical companies as well as small biotech or medical devices companies.